Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737762 · ClinicalTrials.gov registry record · Phase 3
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
A Phase 3 study, sponsored by Healthpoint.
- Completed
- Registry status
- Phase 3
- Development phase
- 155
- Enrollment target
NCT01737762: Completed Phase 3 study, sponsored by Healthpoint.
NCT01737762 is a Phase 3 study that has completed, run by Healthpoint. The registered enrollment target is 155 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737762, a Phase 3 study, has completed, sponsored by Healthpoint.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 155 participants
- Enrollment target
Study Summary
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA). At least 250 subjects will participate. The study is going to be conducted in approximately 50 sites in the United States and Canada.
Primary Outcome
Compare HP802-247 plus compression therapy against Vehicle plus compression therapy for proportion of subjects with complete wound closure over the 16-week treatment period from baseline.
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL HP802-247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT01737762 record still lists
NCT01737762 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01737762 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01737762 about?
NCT01737762 is a clinical study titled "Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2". This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA). At least 250 subjects will participate. The study is going to be con...
What is the current status of trial NCT01737762?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 155 participants. The study started on 2012-11. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01737762?
The interventions under investigation include: Vehicle (BIOLOGICAL), HP802-247 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01737762?
This trial is sponsored by Healthpoint, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01737762's enrollment target sits among peer trials
155 1509th of 2000 higher than 492 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia